SCHEMBL4246314

SCHEMBL4246314

NC(=O)c1nc2cccc(C(=O)NCc3ccc(F)cc3)c2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
KMT2A Q03164 2/20 0.50
HTT P42858 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50
LMNA P02545 3/20 0.46
MAPT P10636 2/20 0.46
MT-CO2 P00403 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
RAB9A P51151 2/20 0.44
ROCK1 Q13464 1/20 0.44
PLA2G7 Q13093 1/20 0.43
AURKA O14965 1/20 0.43
RPS6KB1 P23443 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242333 0.90 AURKA (0.44) SMN1; SMN2KMT2AHTTCYP1A2CYP2C19
SCHEMBL4239959 0.90 SMN1; SMN2 (0.53) SMN1; SMN2KMT2ALMNAMAPTL3MBTL1
SCHEMBL4243703 0.89 ROCK1 (0.46) MAPTRAB9AROCK1AURKARPS6KB1
SCHEMBL4241582 0.89 POLA1 (0.46) SMN1; SMN2KMT2AHTTCYP2C19LMNA
SCHEMBL4239339 0.89 HPGD (0.52) KMT2ALMNAMAPTKDM4EALDH1A1
SCHEMBL4241181 0.87 KMT2A (0.54) KMT2AKDM4EALDH1A1
SCHEMBL4246316 0.86 KMT2A (0.52) SMN1; SMN2KMT2AHTTCYP1A2CYP2C19
SCHEMBL4239186 0.86 HPGD (0.50) SMN1; SMN2KMT2ALMNAMAPTEGLN1
SCHEMBL4246334 0.86 KLKB1 (0.43) SMN1; SMN2KMT2AMAPT
SCHEMBL4244271 0.85 HTR2C (0.49) EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 US disclosed
EP-2457901-A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors High Point Pharmaceuticals, LLC (US) 2012-05-30 EP disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP SMN1; SMN2 1971/4885KMT2A 4094/4885HTT 472/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP SMN1; SMN2 1971/4885KMT2A 4094/4885HTT 472/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP SMN1; SMN2 1971/4885KMT2A 4094/4885HTT 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.